Abstracts tagged "anti-CCP antibodies"

Abstract Number: 2278 • 2013 ACR/ARHP Annual Meeting
Ordering Of Serologic Markers Of Rheumatoid Arthritis Among Primary Care and Subspecialty Providers: Under-Utilization Of Anti-Citrullinated Peptide Antibody Tests By Non-Rheumatologists
Emily H. Glynn¹, Mark H. Wener² and Michael Astion³, ¹Laboratory Medicine, University of Washington, Seattle, WA, ²Rheumatology & Lab Med, University of Washington, Seattle, WA, ³Department of Laboratories, Seattle Children's Hospital, Seattle, WA
Background/Purpose: Anti-citrullinated peptide antibodies (ACPA) are more specific and have a superior positive predictive value for diagnosis of rheumatoid arthritis (RA) compared to RF. The…
Abstract Number: 2197 • 2013 ACR/ARHP Annual Meeting
High Titer IgG Anti-Cyclic Citrullinated Peptide Antibodies Are Associated With Joint Destruction In Juvenile Idiopathic Arthritis Patients
Brooke Gilliam, Lance Feller and Terry L. Moore, Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO
Background/Purpose: IgG anti-cyclic citrullinated peptide (anti-CCP) antibodies have been identified as an important indicator of destructive disease in juvenile idiopathic arthritis (JIA), as is the…
Abstract Number: 1586 • 2013 ACR/ARHP Annual Meeting
Defining Hand Arthritis In Systemic Lupus Erythematosus, From An Ultrasound, Magnetic Resonance Imaging and Antibody Status Perspective
Elisabeth M.A Ball¹, Arthur Grey², Ai Lyn Tan³, Eiji Fukuba⁴, Gunter Steiner⁵, Dennis McGonagle⁶, Aubrey Bell⁷ and Madeleine Rooney⁸, ¹Rheumatology, Queens' University/Musgrave Park Hospital, Belfast, United Kingdom, ²Rheumatology, Musgrave Park Hospital, Belfast, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Department of Radiology, Shimane University, Izuma, Japan, ⁵Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁶NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁷Rheumatology Unit, Musgrave Park Hospital, Belfast, United Kingdom, ⁸Medicine, Queens University Belfast, Belfast, United Kingdom
Background/Purpose: Musculoskeletal involvement in systemic lupus erythematosus (SLE) is common but poorly characterised with only a few Magnetic Resonance Imaging (MRI) or ultrasound (US) studies…
Abstract Number: 1309 • 2013 ACR/ARHP Annual Meeting
Prognosis Of Seronegative Patients In a Large Prospective Cohort Of Patients With Early Inflammatory Arthritis
Lillian J. Barra¹, Janet E. Pope², Boulos Haraoui³, Carol A. Hitchon⁴, J. Carter Thorne⁵, Edward C. Keystone^6,7, Diane Tin⁸, Gilles Boire⁹ and Vivian P. Bykerk¹⁰, ¹Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ³Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁴Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ¹⁰Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Rheumatoid Factor (RF) and anti-Cyclic Citrullinated Peptide (anti-CCP) are believed to be associated with more severe clinical outcomes; however, studies in Early Inflammatory Arthritis…
Abstract Number: 808 • 2013 ACR/ARHP Annual Meeting
A Genome Wide Association Study Of Rheumatoid Arthritis Without Antibodies Against Citrullinated Peptides
Lara Bossini-Castillo¹, Carolien de Kovel², Henrik Kallberg³, Marieke J.H. Coenen⁴, Paul P. Tak⁵, Marcel D. Posthumus⁶, Cisca Wijmenga⁷, Thomas W.J. Huizinga⁸, Annette H.M. van der Helm-van Mil⁹, Luis Rodriguez-Rodriguez¹⁰, Isidoro Gonzalez-Alvaro¹¹, Miguel Angel Gonzalez-Gay¹², Irene E. van der Horst-Bruinsma¹³, B.a.C Dijkmans¹⁴, G. J. Wolbink¹⁵, Roel A. Ophoff², Piet L.C.M. van Riel¹⁶, Lars Klareskog³, J.B.a. Crusius¹⁷, Elisabeth Brouwer¹⁸, Javier Martin¹⁹, Niek de Vries⁵, René E.M. Toes⁹, Leonid Padyukov²⁰ and Bobby P.C. Koeleman²¹, ¹Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ²Department of Medical Genetics, UMCU Utrecht, Utrecht, Netherlands, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Human Genetics (855), Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁶Department of Rheumatology, University of Groningen, University Medical Center, Groningen, Netherlands, ⁷Department of Genetics, University Medical Hospital Groningen, University of Groningen, Groningen, Netherlands, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹⁰Hospital Clínico San Carlos, Department of Rheumatology, Madrid, Spain, ¹¹Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain, ¹²Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander, Santander, Spain, ¹³Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ¹⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ¹⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ¹⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁷Pathology, VU University Medical Center, Amsterdam, Netherlands, ¹⁸Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ¹⁹Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ²⁰Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²¹Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a common autoimmune disease that is associated with a progressive loss of the joints induced by a chronic inflammation of…
Abstract Number: 410 • 2013 ACR/ARHP Annual Meeting
Correlation of Carotid Intima Media Thickness With Interleukin-6, Tumor Necrosis Factor-α and Anti-Cyclic Citrullinated Peptides In Rheumatoid Arthritis
Lourdes Nuñez Atahualpa¹, Mauricio Figuroa Sanchez¹, Daniel Alberto Rocha Muñoz², Raul Vargas Ramirez³, Beatriz Teresita Martin Marquez⁴, Jorge Ivan Gamez Nava⁵, Laura González López⁶, Erika Martínez García³, Esther Sanchez Corona³, Marcelo Petri⁴, Rosa Navarro Hernandez³, Veronica Gonzalez Diaz⁷, Jorge Aguilar Arreola⁸, Ana Guisllaine Bernard Medina⁹, Alejandra Nuñez Atahualpa¹⁰, Javier Andrade Garduño¹⁰, Eduardo Gomez Bañuelos³ and Monica Vazquez Del Mercado^4,8, ¹Radiology, Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico, ²Unidad de Investigación en Epidemiología Clínica del Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, ³CUCS, Universidad de Guadalajara, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético,, Guadalajara, Mexico, ⁴Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ⁵Unidad de Investigación en Epidemiología Clínica, Hospital de Especialidades Centro Médico Nacional de Occidente., Guadalajara, Jalisco, Mexico, ⁶Medicina Interna-Reumatología, Departamento de Medicina Interna-Reumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social., Guadalajara, Jalisco, Mexico, ⁷Reumatologia, Antiguo Hospital Civil de Guadalajara - Fray Antonio Alcalde, Guadalajara, Mexico, ⁸Rheumatology, Hospital Civil Dr Juan I Menchaca, Guadalajara, Mexico, ⁹Rheumatology, Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico, ¹⁰Universidad Autónoma de Guadalajara, Guadalajara, Mexico
Background/Purpose: The main cause of death in rheumatoid arthritis patients are cardiovascular events which cannot be entirely explained by traditional risk factors, suggesting, that systemic…
Abstract Number: 2114 • 2012 ACR/ARHP Annual Meeting
Joint Damage Progression in Rheumatoid Arthritis: Role of the HLA-DRB1 Shared Epitope and Anti-CCP
Jose Felix Restrepo¹, Inmaculada del Rincon¹, Roy W. Haas², Daniel F. Battafarano³ and Agustin Escalante², ¹Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX
Background/Purpose: The HLA-DRB1 shared epitope (SE) and antibodies to cyclic citrullinated peptides (anti-CCP) are important to the susceptibility to rheumatoid arthritis (RA), and are thought…
Abstract Number: 973 • 2012 ACR/ARHP Annual Meeting
New Genetic Risk Loci for the Radiographic Severity of Rheumatoid Arthritis
Diederik P.C. de Rooy¹, Sacha Zhernakova¹, Roula Tsonaka², Fina Kurreeman³, René E.M. Toes¹, Tom W. J. Huizinga⁴, Jeanine Houwing-Duistermaat⁵, Peter K. Gregersen⁶ and Annette H.M. van der Helm-van Mil¹, ¹Rheumatology, Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Medical Statistics, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Rheumatology, Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Statistics, Statistics, Leiden University Medical Center, Leiden, Netherlands, ⁶Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: The severity of joint destruction is highly variable between Rheumatoid Arthritis (RA) patients; approximately 54% of this variance is explained by genetic factors. Many…
Abstract Number: 2116 • 2012 ACR/ARHP Annual Meeting
The Associations of HLA-DR Shared Epitope Alleles and Serum Cytokines Among Postmenopausal Women with Rheumatoid Factor and Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis
Mehret Birru Talabi¹, Rachel Mackey², Larry W. Moreland³, Jan Dorman⁴, Kevin D. Deane⁵, Jeremy Sokolove⁶, V. Michael Holers⁷, William H. Robinson⁸, Brian Wallitt⁹ and Lewis Kuller¹⁰, ¹Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴School of Nursing, University of Pittsburgh School of Nursing, Pittsburgh, PA, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁶Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁸Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁹Washington Hospital Center, Baltimore, MD, ¹⁰Epidemiology, University of Pittsburgh, Pittsburgh, PA
Title: The Associations of HLA-DRβ1 Shared Epitope Alleles and Serum Cytokines Among Postmenopausal Women with Rheumatoid Factor and Anti-Citrullinated Protein Antibody-Positive Rheumatoid ArthritisBackground/Purpose: This study…
Abstract Number: 436 • 2012 ACR/ARHP Annual Meeting
Synthetic Anti-CCP Antibody Aggravated Severity of Animal Arthritis and Captured Citrullinated Antigen in the Serum of Patients with Rheumatoid Arthritis
Youngkyun Kim¹, Su-Jin Moon², Hyoju Yi² and Ji Hyeon Ju³, ¹1Convergent Research Consortium for Immunologic Disease, The Catholic University of Korea, Seoul, South Korea, ²Rheumatology, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Rheumatology, College of Medicine, The Catholic University of Korea & Stanford University, Seoul & Palo Alto, CA
Background/Purpose: Auto-antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the prognosis and diagnosis of rheumatoid arthritis (RA), and have been implicated in…
Abstract Number: 2120 • 2012 ACR/ARHP Annual Meeting
Predictive Value of Anti-CCP Positivity On Disease Course and Response to Therapy in Early Rheumatoid Arthritis. Results From the Swedish EIRA Study
Saedis Saevarsdottir¹, Marie Holmqvist², Johan Askling³, Lars Alfredsson⁴ and Lars Klareskog⁵, ¹Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit & Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden, ⁴Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Does anti-CCP-positivity predict disease course and response to therapy in early rheumatoid arthritis (RA)? Methods: We retrieved clinical follow-up data for patients entering the…
Abstract Number: 439 • 2012 ACR/ARHP Annual Meeting
Interaction of Antibodies Against Citrullinated Peptides with HLA Shared Epitope, PTPN22 1858T Variant, and Smoking in Individuals Prior to and After the Development of Rheumatoid Arthritis
Heidi Kokkonen¹, Mikael Brink², Monika Hansson³, Linda Mathsson⁴, Ewa Lassen⁵, Per Johan Jakobsson⁶, Rikard Holmdahl⁷, Johan Rönnelid⁴, Lars Klareskog⁸ and Solbritt M. Rantapaa-Dahlqvist⁹, ¹Rheumatology, Umeå University, Umea, Sweden, ²Umea University, Umea, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁵Transfusional Medicin, Umeå University, Umeå, Sweden, ⁶Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁷Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, ⁸Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁹Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Umea, Sweden
Background/Purpose: The presence of antibodies against cyclic citrullinated peptides (ACPA) has been demonstrated to precede the development of rheumatoid arthritis (RA) by several years. The…
Abstract Number: 1769 • 2012 ACR/ARHP Annual Meeting
Affinity Purification and Characterisation of Anti-CCP Antibodies From Plasma and Synovial Fluids of Patients with Rheumatoid Arthritis
Elena Ossipova¹, Catia Cerqueira², Evan Reed², Nastya Kharlamova², Lena Israelsson², Rikard Holmdahl³, Anca Catrina², Vivianne Malmström², Yngve Sommarin⁴, Lars Klareskog², Per Johan Jakobsson² and Karin Lundberg², ¹Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, ⁴Euro-Diagnostica AB, Malmö, Sweden
Background/Purpose: Autoimmunity in rheumatoid arthritis (RA) is characterized by autoantibodies to citrullinated proteins/peptides (ACPA). These antibodies (present in 60-70% of patients) antedate clinical onset and…
Abstract Number: 412 • 2012 ACR/ARHP Annual Meeting
Single Nucleotide Polymorphisms within the HLA-DRB1 Gene in Relation to Antibodies Against Citrullinated Peptides in Individuals Prior to the Development of Rheumatoid Arthritis
Lisbeth Arlestig¹, Mikael Brink², Monika Hansson³, Per Johan Jakobsson⁴, Rikard Holmdahl⁵, Linda Mathsson⁶, Johan Ronnelid⁶, Lars Klareskog⁷ and Solbritt M. Rantapaa-Dahlqvist⁸, ¹Rheumatology, Umeå University, Umea, Sweden, ²Umea University, Umea, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, ⁶Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁷Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁸Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Umea, Sweden
Background/Purpose: Multiplex analysis has demonstrated the presence of several antibodies against cyclic citrullinated peptides (ACPA) preceding the development of rheumatoid arthritis (RA) by several years.…
Abstract Number: 1770 • 2012 ACR/ARHP Annual Meeting
Recognition of Citrullinated and Carbamylated Proteins by Human Antibodies: Specificity, Cross-Reactivity and the “AMC-Senshu” Method
Jing Shi¹, George Janssen², Peter van Veelen², Janwouter Drijfhout², Antony Cerami³, Tom Huizinga⁴, Leendert A. Trouw⁵ and René E.M. Toes⁴, ¹Rheumatology, LUMC, Leiden, Netherlands, ²Immunohematology and Bloodbank, LUMC, Leiden, Netherlands, ³Nephrology, LUMC, Leiden, Netherlands, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) play an important role in the diagnosis and prognosis of Rheumatoid Arthritis (RA). The Anti-Modified Citrulline (AMC) (‘Senshu’) method is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.